Daunorubicin in the therapy of acute granulocytic leukemia.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001792:Blood Platelets; D001803:Blood Transfusion; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D006965:Hyperplasia / Q000139:chemically induced; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D006834:Hydrazines; D003561:Cytarabine; D015122:Mercaptopurine; D008727:Methotrexate; D003630:Daunorubicin